Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer

Michael A. Choti

Research output: Contribution to journalComment/debate

6 Scopus citations

Fingerprint Dive into the research topics of 'Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer'. Together they form a unique fingerprint.